TCL Archive Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested February 11, 1977
TCL Archive Health Canada Suspends Avastin Approval; CMS Has Taken No Action After FDA Decision December 2, 2011
TCL Archive In Brief: James Wallace Named CALGB Executive Officer; Gritz Receives First Joseph Cullen Award September 11, 1992
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
